<!DOCTYPE html>
<html lang="en">

<!-- Mirrored from www.eisai.com/news/2022/news202267.html by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 05 Oct 2022 19:34:20 GMT -->
<head>
<!-- ================ ▼ Google Tag Manager ▼ ================ -->
<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-KCCTJRT');</script>
<!-- End Google Tag Manager -->
<!-- ================ ▲ Google Tag Manager ▲ ================ -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<meta name="description" content="Eisai's news release Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma is posted.">
<meta name="keywords" content="Eisai, pharmaceutical company, News Release">
<title>Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma | News Release：2022 | Eisai Co., Ltd.</title>
<meta property="og:title" content="Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma | News Release：2022 | Eisai Co., Ltd.">
<meta property="og:type" content="article">
<meta property="og:description" content="Eisai's news release Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma is posted.">
<meta property="og:url" content="https://www.eisai.com/news/2022/news202267.html">
<meta property="og:image" content="https://www.eisai.com/common/images/ogp.png">
<meta property="og:site_name" content="Eisai Co., Ltd.">
<link rel="shortcut icon" href="https://www.eisai.com/common/images/favicon.ico" type="image/vnd.microsoft.icon">
<link rel="stylesheet" href="https://www.eisai.com/common/css/common.css">
<script src="https://www.eisai.com/common/js/init.js"></script>
</head>
<body>
<!-- ================ ▼ Google Tag Manager ▼ ================ -->
<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KCCTJRT"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->

<!-- Google Tag Manager -->
<noscript><iframe src="http://www.googletagmanager.com/ns.html?id=GTM-PR7J47" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='http://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-PR7J47');</script>
<!-- End Google Tag Manager -->

<!-- ================ ▲ Google Tag Manager ▲ ================ -->

<!-- ================ ▼ header ▼ ================ -->
<!-- I-SEARCH_EXCEPT_TAG_START -->
<header class="site-header">
<div class="header-inner">

<div class="str-inner">
<p class="header-logo"><a href="https://www.eisai.com/index.html"><img src="https://www.eisai.com/common/images/header/logo.svg" alt="/news/index.html"></a></p>
</div><!-- /.str-inner -->

<div class="region-nav js-hamburger-tgl">
<p class="btn-nav js-hamburger-tgl-hook">Menu</p>
<div class="nav-inner js-hamburger-tgl-detail">
<nav class="g-nav">
<ul class="list-g-nav">

<li class="nav-hhc"><a href="https://www.eisai.com/hhc/index.html"><span class="label">Eisai's <abbr title="human health care" class="txt-hhc">hhc</abbr> Concept</span></a>
</li>
<li class="nav-ir js-megadrop have-g-nav-3"><a class="js-megadrop-hook" data-megadrop-expanded="false" href="https://www.eisai.com/ir/index.html"><span class="label">Investors</span></a>
<div class="megadrop-outer js-megadrop-detail">
<div class="megadrop-inner">
<div class="megadrop-wrap">
<a href="#" class="g-nav-back-sp-3 js-back-sp-3">Back</a>
<p class="megadrop-hdg">
<a href="https://www.eisai.com/ir/index.html">Investors</a></p>
<div class="megadrop-contents">
<ul class="megadrop-list lyt-col1">
<li><a class="js-megadrop-parent01" href="https://www.eisai.com/ir/management/index.html">Management Policy</a></li>
<li><a class="js-megadrop-parent02" href="https://www.eisai.com/ir/library/index.html">IR Library</a></li>
<li><a class="js-megadrop-parent03" href="https://www.eisai.com/ir/financial_data/index.html">Financial Data</a></li>
<li><a class="js-megadrop-parent04" href="https://www.eisai.com/ir/event/index.html">IR Events & Calendar</a></li>
<li><a class="js-megadrop-parent05" href="https://www.eisai.com/ir/stock/index.html">Stock & Bond Information</a></li>
<li><a class="no-have-g-nav-4" href="https://reg18.smp.ne.jp/regist/is?SMPFORM=ofr-pjmcp-3eeb4b68adb3d924b271cc153eab1837">E-Mail Alerts</a></li>
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/ir/sitemap/index.html">IR Site Map</a></li>
</ul>
</div>
</div>
<div class="megadrop-wrap2 js-megadrop-child01">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/ir/management/index.html">Management Policy</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/ir/management/strategy/index.html">Medium-Term Business Plan ‘EWAY Future & Beyond’</a></li>
<li><a href="https://www.eisai.com/ir/management/capitalpolicy/index.html">Basic Policy for Capital Strategy</a></li>
<li><a href="https://www.eisai.com/ir/management/basicpolicy.html">Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child02">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/ir/library/index.html">IR Library</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/ir/library/settlement/index.html">Financial Reports</a></li>
<li><a href="https://www.eisai.com/ir/library/report/index.html">Shareholder Reports</a></li>
<li><a href="https://www.eisai.com/ir/library/annual/index.html">Value Creation Report / Environmental Report</a></li>
<li><a href="https://www.eisai.com/ir/library/presentations/index.html">Presentations</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child03">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/ir/financial_data/index.html">Financial Data</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/ir/financial_data/financial_highlight/index.html">Financial Highlights</a></li>
<li><a href="https://www.eisai.com/ir/financial_data/factsheet/index.html">Fact Sheet</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child04">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/ir/event/index.html">IR Events & Calendar</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/ir/event/calendar/index.html">IR Calendar</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child05">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/ir/stock/index.html">Stock & Bond Information</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/ir/stock/stock/index.html">Stock Information</a></li>
<li><a href="https://www.eisai.com/ir/stock/bonds/index.html">Bonds and Ratings</a></li>
<li><a href="https://www.eisai.com/ir/stock/analyst/index.html">Analyst Coverage</a></li>
<li><a href="https://www.eisai.com/ir/stock/meeting/index.html">General Meeting of Shareholders</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<button class="btn-megadrop-close js-megadrop-close js-megadrop-close-2">
<span>Close</span>
</button>
</div>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
</li>
<li class="nav-sustainability js-megadrop have-g-nav-3"><a class="js-megadrop-hook" data-megadrop-expanded="false" href="https://www.eisai.com/sustainability/index.html"><span class="label">Sustainability</span></a>
<div class="megadrop-outer js-megadrop-detail">
<div class="megadrop-inner">
<div class="megadrop-wrap">
<a href="#" class="g-nav-back-sp-3 js-back-sp-3">Back</a>
<p class="megadrop-hdg">
<a href="https://www.eisai.com/sustainability/index.html">Sustainability</a></p>
<div class="megadrop-contents">
<ul class="megadrop-list lyt-col1">
<li><a class="js-megadrop-parent01" href="https://www.eisai.com/sustainability/management/index.html">Sustainability Management</a></li>
<li><a class="js-megadrop-parent02" href="https://www.eisai.com/sustainability/atm/index.html">Improving Access to Medicines</a></li>
<li><a class="js-megadrop-parent03" href="https://www.eisai.com/sustainability/customer/index.html">Relationship with Customers</a></li>
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/sustainability/society/index.html">Relationship with Society</a></li>
<li><a class="js-megadrop-parent04" href="https://www.eisai.com/sustainability/employee/index.html">Relationship with Our Employees</a></li>
<li><a class="js-megadrop-parent05" href="https://www.eisai.com/sustainability/partner/index.html">Relationship with Business Partners</a></li>
<li><a class="js-megadrop-parent06" href="https://www.eisai.com/sustainability/environment/index.html">Environmental Activities</a></li>
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/sustainability/evaluation/index.html">Third-Party Assessment</a></li>
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/sustainability/support/index.html">Support for Disaster-Stricken Areas</a></li>
</ul>
</div>
</div>
<div class="megadrop-wrap2 js-megadrop-child01">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/sustainability/management/index.html">Sustainability Management</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/sustainability/management/attitude/index.html">Eisai's Sustainability</a></li>
<li><a href="https://www.eisai.com/sustainability/management/materiality/index.html">Material Issues</a></li>
<li><a href="https://www.eisai.com/sustainability/management/global_compact/index.html">The United Nations Global Compact</a></li>
<li><a href="https://www.eisai.com/sustainability/management/sdgs/index.html">Initiatives for Sustainable Development Goals</a></li>
<li><a href="https://www.eisai.com/sustainability/management/compliance/index.html">Compliance, Risk Management and Internal Audit</a></li>
<li><a href="https://www.eisai.com/sustainability/management/globaltax/index.html">Global Tax Policy</a></li>
<li><a href="https://www.eisai.com/sustainability/management/sustainabilityadvisory/index.html">Sustainability Advisory Board</a></li>
<li><a href="https://www.eisai.com/sustainability/management/gri/index.html">GRI Content Index</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child02">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/sustainability/atm/index.html">Improving Access to Medicines</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/sustainability/atm/basis/index.html">Our Philosophy</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/management.html">Our Management</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/research.html">Research &amp; Development</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/development.html">Eisai's Business in Emerging and Developing Countries</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/quality.html">Quality Assurance</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/logistics.html">Manufacturing &amp; Distribution</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/product-security.html">Product Security</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/pharmacovigilance.html">Pharmacovigilance</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/intellectual-property.html">Intellectual Property and Access to Medicines</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/advocacy.html">Advocacy</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/approval.html">Approval Status of Global Products</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/medicines/index.html">Initiatives for Lymphatic Filariasis</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/markets/index.html">Other Access to Medicines Initiatives</a></li>
<li><a href="https://www.eisai.com/sustainability/atm/innovation/index.html">Infectious Diseases Research & Development</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child03">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/sustainability/customer/index.html">Relationship with Customers</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/sustainability/customer/supply/index.html">Stable Supply</a></li>
<li><a href="https://www.eisai.com/sustainability/customer/quality/index.html">Quality Assurance</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child04">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/sustainability/employee/index.html">Relationship with Our Employees</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/sustainability/employee/training/index.html">Development of Human Resources</a></li>
<li><a href="https://www.eisai.com/sustainability/employee/environment/index.html">Positive Work Environment</a></li>
<li><a href="https://www.eisai.com/sustainability/employee/diversity/index.html">Diversity Initiatives</a></li>
<li><a href="https://www.eisai.com/sustainability/employee/human_rights/index.html">Respect for Human Rights</a></li>
<li><a href="https://www.eisai.com/sustainability/employee/health_safety/index.html">Occupational Safety and Health</a></li>
<li><a href="https://www.eisai.com/sustainability/employee/health_declaration/index.html">Eisai Health Declaration</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child05">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/sustainability/partner/index.html">Relationship with Business Partners</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/sustainability/partner/global_procurement_standard/index.html">Eisai Global Procurement Standard</a></li>
<li><a href="https://www.eisai.com/sustainability/partner/partnership/index.html">Eisai's Partnership Initiatives</a></li>
<li><a href="https://www.eisai.com/sustainability/partner/contact/index.html">Contact Us</a></li>
<li><a href="https://www.eisai.com/sustainability/partner/purchase-process/index.html">Purchasing Process</a></li>
<li><a href="https://www.eisai.com/sustainability/partner/guidelines/index.html">Eisai Global Code of Conduct for Business Partners</a></li>
<li><a href="https://www.eisai.com/sustainability/partner/sustainableprocurement/index.html">Sustainable Procurement</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child06">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/sustainability/environment/index.html">Environmental Activities</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/sustainability/environment/carbon-neutral/index.html">Eisai's Statement of Commitment for Carbon Neutrality by 2040</a></li>
<li><a href="https://www.eisai.com/sustainability/environment/vision/index.html">Environmental Vision</a></li>
<li><a href="https://www.eisai.com/sustainability/environment/management/index.html">Environmental Management</a></li>
<li><a href="https://www.eisai.com/sustainability/environment/low-carbon/index.html">Initiatives for the Formation of a Carbon-free Society</a></li>
<li><a href="https://www.eisai.com/sustainability/environment/circulation-type/index.html">Establishment of a Recycling-Oriented Society</a></li>
<li><a href="https://www.eisai.com/sustainability/environment/chemical_management/index.html">Management of Chemical Substances</a></li>
<li><a href="https://www.eisai.com/sustainability/environment/resource-saving/index.html">Saving Resources</a></li>
<li><a href="https://www.eisai.com/sustainability/environment/biodiversity_conservation/index.html">Biodiversity Conservation</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<button class="btn-megadrop-close js-megadrop-close js-megadrop-close-2">
<span>Close</span>
</button>
</div>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
</li>
<li class="nav-company js-megadrop have-g-nav-3"><a class="js-megadrop-hook" data-megadrop-expanded="false" href="https://www.eisai.com/company/index.html"><span class="label">About Eisai</span></a>
<div class="megadrop-outer js-megadrop-detail">
<div class="megadrop-inner">
<div class="megadrop-wrap">
<a href="#" class="g-nav-back-sp-3 js-back-sp-3">Back</a>
<p class="megadrop-hdg">
<a href="https://www.eisai.com/company/index.html">About Eisai</a></p>
<div class="megadrop-contents">
<ul class="megadrop-list lyt-col1">
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/company/message/index.html">Message from Top Management</a></li>
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/company/philosophy/index.html">Corporate Concept</a></li>
<li><a class="js-megadrop-parent01" href="https://www.eisai.com/company/profile/index.html">Corporate Information</a></li>
<li><a class="js-megadrop-parent02" href="https://www.eisai.com/company/governance/index.html">Corporate Governance</a></li>
<li><a class="js-megadrop-parent03" href="https://www.eisai.com/company/business/index.html">Business Activities</a></li>
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/company/video/index.html">Video Library</a></li>
<li><a class="no-have-g-nav-4" href="https://www.eisai.com/company/glance/index.html">Eisai at a Glance</a></li>
</ul>
</div>
</div>
<div class="megadrop-wrap2 js-megadrop-child01">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/company/profile/index.html">Corporate Information</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/company/profile/officer/index.html">Corporate Executives</a></li>
<li><a href="https://www.eisai.com/company/profile/office/index.html">Japan Business Sites</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Eisai Group Worldwide</a></li>
<li><a href="https://www.eisai.com/company/profile/history/index.html">Eisai: The First 80 Years</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child02">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/company/governance/index.html">Corporate Governance</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/company/governance/cgregulations/index.html">Related Rules</a></li>
<li><a href="https://www.eisai.com/company/governance/cgsystem/index.html">Our Corporate Governance System</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<div class="megadrop-wrap2 js-megadrop-child03">
<button class="btn-megadrop-close js-megadrop-close">
<span>Close</span>
</button>
<a href="#" class="g-nav-back-sp-4 js-back-sp-4">Back</a>
<p class="megadrop-hdg2"><a href="https://www.eisai.com/company/business/index.html">Business Activities</a></p>
<ul class="megadrop-list2">
<li><a href="https://www.eisai.com/company/business/products/index.html">Products</a></li>
<li><a href="https://www.eisai.com/company/business/nerve/index.html">Neurology Area</a></li>
<li><a href="https://www.eisai.com/company/business/cancer/index.html">Oncology Area</a></li>
<li><a href="https://www.eisai.com/company/business/ecosystem/index.html"><abbr title="human health care" class="txt-hhc display-contents">hhc</abbr>eco (the <abbr title="human health care" class="txt-hhc display-contents">hhc</abbr> philosophy + ecosystem)</a></li>
<li><a href="https://www.eisai.com/company/business/research/index.html">R&amp;D</a></li>
<li><a href="https://www.eisai.com/company/business/production/index.html">Production and Logistics (Demand Chain Systems)</a></li>
<li><a href="https://www.eisai.com/company/business/marketing/index.html">Marketing</a></li>
</ul>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
<button class="btn-megadrop-close js-megadrop-close js-megadrop-close-2">
<span>Close</span>
</button>
</div>
<div class="sub-nav pc-none">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close pc-none"><span class="label">Close</span></button>
</div>
</li>

</ul>
</nav>

<div class="sub-nav">
<div class="str-inner">
<ul class="list-sub-nav">
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/company/profile/group/index.html">Worldwide</a></li>
<li><a href="https://www.eisai.co.jp/sustainability/index.html" class="no-icon js-dir">Japanese</a></li>
<li><a href="https://www.eisai.com/inquiry/index.html">Contact Us</a></li>
<li class="sub-nav-search">
<div class="header-search">
<div class="str-inner">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<input type="text" name="kw" value="" class="iSearchAssist" placeholder="Search"><button name="submit" class="btn-input"><span class="label">Search</span><img src="https://www.eisai.com/common/images/icon_search.png" alt=""></button>
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="sort" value="s">
<input type="hidden" name="cond[]" value="all">
<input type="hidden" name="pdf" value="on">
</form>
</div><!-- /.str-inner -->
</div><!-- /.header-search -->
</li>
</ul>
</div><!-- /.str-inner -->
</div>
<button class="btn-nav-close js-hamburger-tgl-close"><span class="label">Close</span></button>
</div><!-- /.nav-inner -->
</div><!-- /.region-nav -->
</div><!-- /.header-inner -->
</header><!-- /.site-header -->
<!-- I-SEARCH_EXCEPT_TAG_END -->
<!-- ================ ▲ header ▲ ================ -->

<div class="site-content">

<div class="str-inner">
<ul class="list-breadcrumb">
<li><a href="https://www.eisai.com/index.html">Home</a></li>
<li><a href="https://www.eisai.com/news/index.html">News Release</a></li>
<li><a href="https://www.eisai.com/news/index.html">2022 Release</a></li>
<li><em>Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma</em></li>
</ul>
</div><!-- /.str-inner -->

<div class="region-hdg">
<div class="str-inner">
<h1 class="hdg-06">Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma<span class="sub">Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022</span></h1>
</div>
</div><!-- /.region-hdg -->

<div class="str-inner type-left">
<div class="region-main">
<main>

<!-- ================ ▼ main-contents ▼ ================ -->

<ul class="news-data">
<li><a class="link link-size" href="https://www.eisai.com/news/2022/pdf/enews202267pdf.pdf" target="_blank">For Print</a></li>
<li>September 12, 2022</li>
</ul>

<p>TOKYO and RAHWAY, N.J., September 12, 2022 &ndash; Eisai (Headquarters: Tokyo, CEO: Haruo Naito, &ldquo;Eisai&rdquo;) and Merck &amp; Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 trial investigating LENVIMA<b><sup>&reg;</sup></b>, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA<b><sup>&reg;</sup></b>, the anti-PD-1 therapy from Merck &amp; Co., Inc., Rahway, NJ, USA versus LENVIMA monotherapy, as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Results are being presented during a proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2022, being held in Paris, France and virtually from Sept. 9-13 (abstract #LBA34).</p>
<p>In the final analysis of the trial, there was a trend toward improvement for one of the study&rsquo;s dual primary endpoints, overall survival (OS), for patients treated with LENVIMA plus KEYTRUDA versus LENVIMA monotherapy; however, the results did not meet statistical significance per the pre-specified statistical plan (HR=0.84 [95% CI: 0.71-1.00]; p=0.0227). The median OS was 21.2 months (95% CI: 19.0-23.6) for LENVIMA plus KEYTRUDA and 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy. Additionally, treatment with LENVIMA plus KEYTRUDA resulted in a trend toward improvement in the trial&rsquo;s other dual primary endpoint of progression-free survival (PFS) versus LENVIMA monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance (HR=0.87 [95% CI: 0.73-1.02]; p=0.0466).</p>
<p>&nbsp;</p>
<p>&nbsp;&ldquo;The LEAP-002 trial reflects our research strategy to build on evolving standards of care to further improve outcomes for more people with unresectable hepatocellular carcinoma,&rdquo; said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck &amp; Co., Inc., Rahway, NJ, USA Research Laboratories. &ldquo;The median overall survival of 21.2 months seen with KEYTRUDA plus LENVIMA provides critical insights for further research into the potential role of this combination.&rdquo;</p>
<p>&ldquo;While the outcome is not what we had hoped, it is important for us to see that patients in the trial treated with LENVIMA monotherapy had a median overall survival of 19.0 months,&rdquo; said Corina Dutcus, M.D., Senior Vice President, Clinical Research, Oncology at Eisai Inc. &ldquo;Findings from the LEAP-002 trial will not only help advance our understanding and application of LENVIMA plus KEYTRUDA across our clinical development program but will also provide physicians with additional information on LENVIMA monotherapy&rsquo;s use in unresectable hepatocellular carcinoma, where it is currently approved as a treatment option in multiple regions around the world, including the U.S., the European Union (EU), Japan and China.&rdquo;</p>
<p>LENVIMA monotherapy is approved for the first-line treatment of patients with uHCC in the U.S., the EU and China and for patients with uHCC in Japan. The approval of LENVIMA was based on results of the Phase 3 REFLECT trial, which evaluated the efficacy and safety of LENVIMA versus sorafenib for the first-line treatment of patients with uHCC.</p>
<p>LENVIMA (marketed as KISPLYX<sup>&reg;</sup> for renal cell carcinoma [RCC] in the EU) plus KEYTRUDA is approved in the U.S., the EU and Japan for the treatment of certain types of advanced endometrial carcinoma and advanced RCC. Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in multiple tumor types, including but not limited to endometrial carcinoma, HCC, melanoma, non-small cell lung cancer, RCC, head and neck cancer, colorectal cancer, gastric cancer and esophageal cancer, across more than 15 clinical trials.</p>
<p><b>&nbsp;</b></p>
<p><b>LEAP-002 study design and final analysis results (abstract #LBA34)</b></p>
<p>LEAP-002 is a multicenter, randomized, double-blinded, active-controlled Phase 3 trial (ClinicalTrials.gov, <a href="https://clinicaltrials.gov/ct2/show/NCT03713593">NCT03713593</a>) evaluating LENVIMA plus KEYTRUDA versus LENVIMA monotherapy for the first-line treatment of adult patients with uHCC. Patients were randomized 1:1 to receive LENVIMA (12 mg orally once daily [for patients with screening body weight of at least 60 kg] or 8 mg orally once daily [for patients with screening body weight less than 60 kg]) plus KEYTRUDA (200 mg intravenously [IV] on Day 1 of each three-week cycle); or LENVIMA (12 mg orally once daily [for patients with screening body weight of at least 60 kg] or 8 mg orally once daily [for patients with screening body weight less than 60 kg]) plus saline placebo (IV administered on Day 1 of each three-week cycle). LENVIMA was administered until progressive disease or unacceptable toxicity. KEYTRUDA/placebo was administered for up to 35 cycles (approximately two years).</p>
<p>The dual primary endpoints were PFS, as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1; RECIST v1.1 has been modified for this study to follow a maximum of 10 target lesions in total and a maximum of five target lesions per organ), and OS. Objective response rate (ORR), as assessed by BICR per RECIST v1.1, was a key secondary endpoint. The trial was designed with two interim analyses and a final analysis for OS. Pre-specified efficacy boundaries were one-sided p=0.002 for PFS at interim analysis 1 and p=0.0185 for OS at the final analysis.</p>
<p>As of the data cut-off for the final analysis (June 21, 2022), a total of 794 patients were enrolled and treated, with a median follow-up of 32.1 months (range, 25.8-41.1). A total of 534 OS events had occurred, with 36 patients (9.1%) in the combination arm and 24 patients (6.1%) in the LENVIMA monotherapy arm remaining on study treatment.</p>
<p>The median OS was 21.2 months (95% CI: 19.0-23.6) for LENVIMA plus KEYTRUDA versus 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy at the final analysis. The median PFS was 8.2 months (95% CI, 6.4-8.4) for LENVIMA plus KEYTRUDA versus 8.0 months (95% CI: 6.3-8.2) for LENVIMA monotherapy at the first interim analysis and 8.2 months (95% CI: 6.3-8.3) versus 8.1 months (95% CI: 6.3-8.3), respectively, at the final analysis. The ORR was 26.1% (95% CI: 21.8-30.7) for LENVIMA plus KEYTRUDA versus 17.5% (95% CI: 13.9-21.6) for LENVIMA monotherapy at the final analysis. Median duration of response was 16.6 months (range, 2.0+ to 33.6+) in the KEYTRUDA plus LENVIMA arm versus 10.4 months (range, 1.9 to 35.1+) in the LENVIMA monotherapy arm at the final analysis.</p>
<p>The safety profile of LENVIMA plus KEYTRUDA was consistent with previously reported data on the combination. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 61.5% of patients treated with LENVIMA plus KEYTRUDA versus 56.7% of patients treated with LENVIMA monotherapy. Grade 5 TRAEs occurred in 1.0% of patients treated with LENVIMA plus KEYTRUDA versus 0.8% of patients treated with LENVIMA monotherapy. In patients treated with LENVIMA plus KEYTRUDA, the five most common TRAEs of any grade were hypertension (43.3%), diarrhea (40.3%), hypothyroidism (40.0%), palmar-plantar erythrodysesthesia (PPE) syndrome (33.2%) and proteinuria (30.6%). In patients treated with LENVIMA monotherapy, the five most common TRAEs of any grade were hypertension (46.8%), hypothyroidism (35.7%), proteinuria (34.9%), diarrhea (33.9%) and PPE syndrome (30.6%). Post-study systematic anti-cancer treatments were given for 44.1% of patients receiving LENVIMA plus KEYTRUDA versus 52.1% of those receiving LENVIMA monotherapy.</p>
<p>&nbsp;</p>
<p></p>
<p>&nbsp;</p>
<ul class="box-contact js-adjust-h">
<li class="wrap">
<p class="hdg js-set-h-01">Eisai Co., Ltd.</p>
<div class="content-wrap js-set-h-02">
<div class="content-inner">
<p><span class="txt-b">Public Relations:</span></p>
<p>+81-(0)3-3817-5120</p>
<p>&nbsp;&nbsp;</p>
<p>&nbsp;&nbsp;</p>
<p><span class="txt-b">Investor Relations:</span></p>
<p>+81-(0) 70-8688-9685</p>
</div>
</div>
</li>
<li class="wrap">
<p class="hdg js-set-h-01">Merck &amp; Co., Inc., Kenilworth, N.J., U.S.A.</p>
<div class="content-wrap js-set-h-02">
<div class="content-inner">
<p><span class="txt-b">Media Relations</span></p>
<p>Melissa Moody: +1-(215) 407-3536</p>
<p>Nikki Sullivan: +1-(718) 644-0730</p>
<p>&nbsp;</p>
<p><span class="txt-b">Investor Relations</span></p>
<p>Peter Dannenbaum: +1- (908) 740-1037</p>
Damini Chokshi: +1-(908) 740- 1807</div>
</div>
</li>
</ul>
<p class="Default"><b>&nbsp;</b></p>
<p><b>About hepatocellular carcinoma (HCC)</b><b></b></p>
<p>Hepatocellular carcinoma is the most common type of primary liver cancer<sup>1</sup> and the most rapidly increasing cause of cancer deaths in the United States.<sup>2</sup> Hepatocellular carcinoma accounts for approximately 90% of primary liver cancers.<sup>3</sup> It is estimated there were more than 905,000 new cases of liver cancer and more than 830,000 deaths from the disease globally in 2020,<sup>4</sup> making it the sixth most frequently diagnosed cancer worldwide<sup>5</sup> and one of the leading causes of cancer deaths around the world. In Japan, it is estimated there were more than 45,000 new cases of liver cancer diagnosed and more than 28,000 deaths from this disease in 2020.<sup>6</sup> In the United States, it is estimated there will be over 41,000 new cases of liver cancer and over 30,000 deaths from this disease in 2022.<sup>5</sup> Risk factors for liver cancer include gender, ethnicity, chronic viral hepatitis (Hep-B or Hep-C) infection, cirrhosis, alcohol use and metabolic syndrome.<sup>7</sup> Hepatocellular carcinoma, which is often diagnosed at an advanced stage,<sup>8</sup> has a five-year survival rate of approximately 20% in the United States.<sup>9</sup></p>
<p>&nbsp;</p>
<p><b>About LENVIMA</b><b><sup>&reg;</sup></b><b> (lenvatinib) Capsules</b></p>
<p>LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine　kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFR&alpha;), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.</p>
<p>&nbsp;</p>
<p><i>Thyroid cancer</i></p>
<p>・Indication as monotherapy</p>
<p>(Approved in over 80 countries including Japan, the United States, China, and countries in Europe and Asia)</p>
<p>Japan: Radically unresectable thyroid cancer</p>
<p>The United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)</p>
<p>Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H&uuml;rthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)</p>
<p>&nbsp;</p>
<p><i>Hepatocellular carcinoma</i></p>
<p>・Indication as monotherapy</p>
<p>(Approved in over 80 countries including Japan, the United States, China, and countries in Europe and Asia)</p>
<p>Japan: Unresectable hepatocellular carcinoma</p>
<p>The United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)</p>
<p>Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy</p>
<p>&nbsp;</p>
<p><i>Thymic carcinoma</i></p>
<p>・Indication as monotherapy (Approved in Japan)</p>
<p>Japan: Unresectable thymic carcinoma</p>
<p>&nbsp;</p>
<p><i>Renal cell carcinoma</i> (In Europe, the agent was launched under the brand name Kisplyx<sup>&reg;</sup>)</p>
<p>・Indication in combination with everolimus</p>
<p>(Approved in over 65 countries including the United States, and countries in Europe and Asia)</p>
<p>The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy</p>
<p>Europe: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy</p>
<p>・Indication in combination with KEYTRUDA (generic name: pembrolizumab)</p>
<p>(Approved in over 40 countries including Japan, the United States, and countries in Europe and Asia)</p>
<p>Japan: Radically unresectable or metastatic renal cell carcinoma</p>
<p>The United States: The first-line treatment of adult patients with advanced renal cell carcinoma</p>
<p>Europe: The first-line treatment of adult patients with advanced renal cell carcinoma</p>
<p>&nbsp;</p>
<p><i>Endometrial carcinoma </i></p>
<p>・Indication in combination with KEYTRUDA</p>
<p>(Approved [including conditional approval] in over 45 countries including Japan, the United States, and countries in Europe and Asia)</p>
<p>Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy</p>
<p>The United States: The treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.</p>
<p>Europe: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery</p>
<p><strong>&nbsp;</strong></p>
<p><span class="txt-b">About KEYTRUDA<sup>&reg;</sup>&nbsp;(pembrolizumab) Injection, 100mg</span></p>
<p>KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body&rsquo;s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.</p>
<p>Merck &amp; Co., Inc., Rahway, NJ, USA has the industry&rsquo;s largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.</p>
<p>&nbsp;</p>
<p><span class="txt-b">About Eisai and the Merck <b>&amp; Co., Inc., Rahway, NJ, USA</b> Collaboration</span><b></b></p>
<p>In March 2018, Eisai and Merck &amp; Co., Inc., Rahway, NJ, USA, known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck &amp; Co., Inc., Rahway, NJ, USA.</p>
<p>In addition to ongoing clinical studies evaluating the LENVIMA plus KEYTRUDA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in multiple tumor types across more than 15 clinical trials.</p>
<p><strong>&nbsp;</strong></p>
<p><b>Eisai&rsquo;s Focus on Cancer</b><b></b></p>
<p>Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (<i>Ricchi</i>) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these <i>Ricchi</i>, with the aim of contributing to the cure of cancers.</p>
<p>&nbsp;</p>
<p><b>About Eisai</b></p>
<p>Eisai&rsquo;s Corporate Concept is &ldquo;to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.&rdquo; Under this Concept [also known as our <i>human health care</i> (<i>hhc</i>) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&amp;D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.</p>
<p>In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.</p>
<p>For more information about Eisai, please visit <a href="http://www.eisai.com/">www.eisai.com</a> (for global headquarters: Eisai. Co., Ltd.), <a href="http://us.eisai.com/">us.eisai.com</a> (for U.S. headquarters: Eisai, Inc.) or <a href="http://www.eisai.co.uk/">www.eisai.eu</a> (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on Twitter (<a href="https://twitter.com/eisaius">U.S</a><span style="text-decoration: underline;">.</span> and <a href="https://twitter.com/eisai_sdgs">global</a>) and LinkedIn (for <a href="https://www.linkedin.com/company/eisai/">U.S.</a> and <a href="https://www.linkedin.com/company/eisai-emea/">EMEA</a>).</p>
<p><em>&nbsp;</em></p>
<p><b>Merck </b><b>&amp; Co., Inc., Rahway, NJ, USA</b><b>&rsquo;s Focus on Cancer</b></p>
<p><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b>Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck &amp; Co., Inc., Rahway, NJ, USA, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck &amp; Co., Inc., Rahway, NJ, USA is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit <a href="http://www.merck.com/clinicaltrials">www.merck.com/clinicaltrials</a>.</p>
<p>&nbsp;</p>
<p><b>About Merck </b><b>&amp; Co., Inc., Rahway, NJ, USA</b><b>　</b><b></b></p>
<p>For over 130 years, Merck &amp; Co., Inc., Rahway, NJ, USA, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world&rsquo;s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck &amp; Co., Inc., Rahway, NJ, USA continues to be at the forefront of research to prevent and treat diseases that threaten people and animals &ndash; including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases &ndash; as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a href="http://www.merck.com/">www.merck.com</a>&nbsp;and&nbsp;connect with us on <a href="https://twitter.com/Merck">Twitter</a>, <a href="https://www.facebook.com/MerckInvents/">Facebook</a>, <a href="https://www.instagram.com/merck/">Instagram</a>, <a href="https://www.youtube.com/user/Merck">YouTube</a> and <a href="https://www.linkedin.com/company/merck">LinkedIn</a>.</p>
<p>&nbsp;</p>
<p><b>Forward-Looking Statement of Merck &amp; Co., Inc., Rahway, NJ, USA</b><b></b></p>
<p>This news release of Merck &amp; Co., Inc., Rahway, NJ, USA (the &ldquo;company&rdquo;) includes &ldquo;forward-looking statements&rdquo; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company&rsquo;s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.</p>
<p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company&rsquo;s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company&rsquo;s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.</p>
<p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2021　and the company&rsquo;s other filings with the Securities and Exchange Commission (SEC) available at the SEC&rsquo;s Internet site (<a href="http://www.sec.gov/">www.sec.gov</a>).</p>
<p><sup>&nbsp;</sup></p>
<p><sup>&nbsp;</sup></p>
<p><sup>1</sup>&nbsp; American Cancer Society website, &ldquo;What Is Liver Cancer ?&rdquo; accessed 7/27/2022:</p>
<p><a href="https://www.cancer.org/cancer/liver-cancer/about/what-is-liver-cancer.html">https://www.cancer.org/cancer/liver-cancer/about/what-is-liver-cancer.html</a> .</p>
<p><sup>2</sup>&nbsp; Josep M. L., et. Al. Hepatocellular carcinoma. <i>Nature Reviews Disease Primers.</i> 2021 Jan 21; 7, Article number: 6</p>
<p><a href="https://www.nature.com/articles/s41572-020-00240-3.pdf">https://www.nature.com/articles/s41572-020-00240-3.pdf</a></p>
<p><sup>3</sup> Eunsun K., et al. Hepatocellular carcinoma: old friends and new tricks. <i>Experimental &amp; Molecular Medicine </i><i>Cancer.</i> 2020.　Dec;52(12):1898-1907. <a href="https://www.nature.com/articles/s12276-020-00527-1.pdf">https://www.nature.com/articles/s12276-020-00527-1.pdf</a> .</p>
<p><sup>4</sup>&nbsp; International Agency for Research on Cancer, World Health Organization. &ldquo;Liver Fact Sheet.&rdquo; Cancer Today, 2020. 
<br>
 <a href="https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf">https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf</a> .</p>
<p><sup>5</sup>&nbsp; American Cancer Society website, &ldquo;Key Statistics About Liver Cancer.&rdquo; accessed 7/27/2022:</p>
<p><a href="https://www.cancer.org/cancer/liver-cancer/about/what-is-key-statistics.html">https://www.cancer.org/cancer/liver-cancer/about/what-is-key-statistics.html</a> .</p>
<p><sup>6</sup>&nbsp; International Agency for Research on Cancer, World Health Organization. &ldquo;Japan Fact Sheet.&rdquo; Cancer Today, 2020. 
<br>
 <a href="https://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf">https://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf</a> . <sup></sup></p>
<p><sup>7</sup>&nbsp; American Cancer Society website, &ldquo;Liver Cancer Risk Factors.&rdquo; accessed 7//27/2022:</p>
<p><a href="https://www.cancer.org/cancer/liver-cancer/causes-risks-prevention/risk-factors.html">https://www.cancer.org/cancer/liver-cancer/causes-risks-prevention/risk-factors.html</a> .</p>
<p><sup>8</sup>&nbsp; Stefano C., et al. Challenges of advanced hepatocellular carcinoma. <i>World J Gastroenterol. </i>2016 Sep 14; 22(34): 7645&ndash;7659.<i></i></p>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016365/pdf/WJG-22-7645.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016365/pdf/WJG-22-7645.pdf</a> .</p>
<p><sup>9</sup>&nbsp; National Cancer Institute. &ldquo;SEER Cancer Statistics Review 1975-2016.&rdquo;<i></i></p>
<p><a href="https://seer.cancer.gov/archive/csr/1975_2016/results_merged/topic_survival.pdf">https://seer.cancer.gov/archive/csr/1975_2016/results_merged/topic_survival.pdf</a> .</p>
<p align="center">&nbsp;</p>

<ul class="link-list txt-right">
<li><a href="https://www.eisai.com/news/2022/pdf/enews202267pdf.pdf" target="_blank" class="link-size">Full text</a></li>
</ul>


<!-- I-SEARCH_EXCEPT_TAG_START -->
<div class="lyt-search">
<form name="search_form" action="https://site-search.eisai.co.jp/eng/" method="GET" onsubmit="return mysearch_en(this);">
<label for="sfglobal" class="txt">News release search</label>
<input type="text" name="kw" value="" class="iSearchAssist input" placeholder="Search">
<input type="hidden" name="ie" value="u">
<input type="hidden" name="temp" value="en">
<input type="hidden" name="cond[]" value="news">
<input type="hidden" name="pdf" value="off">
<input type="hidden" name="sort" value="m">
<button name="submit" class="btn">Search</button>
</form>
</div>
<!-- I-SEARCH_EXCEPT_TAG_END -->

<!-- ================ ▲ main-contents ▲ ================ -->

</main>
</div><!-- /.region-main -->
<!-- ================ ▼ side-nav ▼ ================ -->
<!-- I-SEARCH_EXCEPT_TAG_START -->
<div class="region-aside">

<h2 class="side-nav-hdg"><a href="https://www.eisai.com/news/index.html">News Release</a></h2>
<ul class="side-nav side-nav-news">
<li><a href="https://www.eisai.com/news/index.html#2022" class="hash-anchor">2022 Release</a></li>
<li><a href="https://www.eisai.com/news/index.html#2021">2021 Release</a></li>
<li><a href="https://www.eisai.com/news/2020/index.html">2020 Release</a></li>
<li><a href="https://www.eisai.com/news/2019/index.html">2019 Release</a></li>
<li><a href="https://www.eisai.com/news/2018/index.html">2018 Release</a></li>
<li><a href="https://www.eisai.com/news/index2017.html">2017 Release</a></li>
<li><a href="https://www.eisai.com/news/index2016.html">2016 Release</a></li>
<li><a href="https://www.eisai.com/news/index2015.html">2015 Release</a></li>
<li><a href="https://www.eisai.com/news/index2014.html">2014 Release</a></li>
<li><a href="https://www.eisai.com/news/index2013.html">2013 Release</a></li>
<li><a href="https://www.eisai.com/news/index2012.html">2012 Release</a></li>
<li><a href="https://www.eisai.com/news/index2011.html">2011 Release</a></li>
<li><a href="https://www.eisai.com/news/index2010.html">2010 Release</a></li>
<li><a href="https://www.eisai.com/news/index2009.html">2009 Release</a></li>
<li><a href="https://www.eisai.com/news/index2008.html">2008 Release</a></li>
<li><a href="https://www.eisai.com/news/index2007.html">2007 Release</a></li>
</ul>


</div><!-- /.region-aside -->
<!-- I-SEARCH_EXCEPT_TAG_END -->
<!-- ================ ▲ side-nav ▲ ================ -->
</div><!-- /.str-inner -->
</div><!-- /.site-content -->

<!-- ================ ▼ footer ▼ ================ -->
<!-- I-SEARCH_EXCEPT_TAG_START -->
<footer class="site-footer">
<div class="str-inner">
<p id="to-top"><a href="#top"><img src="https://www.eisai.com/common/images/footer/to-top.png" alt="Back to Top"></a></p>
<p class="footer-logo"><img src="https://www.eisai.com/common/images/logo_hhc.svg" alt="hhc human health care"></p>
<div class="footer-utility">
<ul class="footer-nav">
<li><a href="https://www.eisai.com/sitemap/index.html">Sitemap</a></li>
<li><a href="https://www.eisai.com/privacy/index.html">Privacy Policy</a></li>
<li><a href="https://www.eisai.com/aboutsite/index.html">Terms of Use</a></li>
<li><a href="https://www.eisai.com/community_guidelines/index.html">SNS Community Guidelines</a></li>
<li><a href="https://www.eisai.com/accessibility/index.html">Accessibility</a></li>
</ul>
<p class="link-tw"><a href="https://twitter.com/Eisai_SDGs" class="no-icon" target="_blank"><img src="https://www.eisai.com/common/images/icon_tw_02.png" alt="">Twitter</a>Eisai official account</p>
</div>
<p class="copyright"><small>Copyright &copy;  <a href="https://www.myknot.club/">MyKnot</a>, Ltd. All Rights Reserved.</small></p>
</div><!-- /.str-inner -->
</footer><!-- /.site-footer -->
<script type="text/javascript" src="https://cache.dga.jp/s/eisai/search_tool_n3.js"></script>
<!-- I-SEARCH_EXCEPT_TAG_END -->
<!-- ================ ▲ footer ▲ ================ -->

<script src="https://www.eisai.com/common/js/jquery-3.2.1.min.js"></script>
<script src="https://www.eisai.com/common/js/run.js"></script>
</body>

<!-- Mirrored from www.eisai.com/news/2022/news202267.html by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 05 Oct 2022 19:34:20 GMT -->
</html>